Upcoming Earnings Overview
The upcoming earnings report for Ionis Pharmaceuticals, Inc. is scheduled for Tuesday, April 28th. Analysts' consensus estimate for earnings per share stands at -0.86.
Live Analysis
Ionis Pharmaceuticals, Inc. is currently priced at $72.2, showing a decrease of -3.09 cents (-0.043%) from the previous close of $72.23. The trading volume is at $304,131, representing a 14.5% deviation from the average.
Performance Streak
The asset has experienced a three-day streak with a price drop of -$2.63 (-3.52%), starting at $74.83.
Earnings Overview
In the latest earnings report on Tuesday, February 24th, Ionis Pharmaceuticals reported an earnings per share of -1.23667, with a consensus estimate revenue of $156 million.
Grades
Morgan Stanley's recent grade for Ionis Pharmaceuticals was upgraded to "Overweight," maintaining the previous rating. The action advised is to hold, with the price at publishing being $74.87 on April 21st.
Cash Flow
The company experienced a net change in cash of $33.92 million, ending the period with $372.26 million in cash.
Income Statement
Ionis Pharmaceuticals reported a net loss of $229 million in the latest financial period, with an earnings per share of -$1.41.
Ratios
Key ratios show a quick ratio of 3.81, gross profit margin of 96.06%, and return on equity of -46.82%.
Balance Sheet
The total assets for Ionis Pharmaceuticals amount to $3.52 billion, with total liabilities at $3 billion, and net debt at $2.24 billion.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.